Codrug: an Efficient Approach for Drug Optimization

Overview

Journal Eur J Pharm Sci

Specialties Chemistry
Pharmacology

Date 2010 Oct 5

PMID 20888411

Citations 27

Authors

N Das

M Dhanawat

B Dash

R C Nagarwal

S K Shrivastava

Affiliations

Soon will be listed here.

Abstract

Codrug or mutual prodrug is an approach where various effective drugs, which are associated with some drawbacks, can be modified by attaching with other drugs of same or different categories directly or via a linkage. More appropriately one can say combining two different pharmacophores with similar or different pharmacological activities elicit synergistic action or help to target the parent drug to specific site/organ/cells respectively. This approach is commonly used to improve physicochemical, biopharmaceutical and drug delivery properties of therapeutic agents.

Citing Articles

Synthesis of Enantiostructured Triacylglycerols Possessing a Saturated Fatty Acid, a Polyunsaturated Fatty Acid and an Active Drug Intended as Novel Prodrugs.

Jonsdottir L, Haraldsson G Molecules. 2024; 29(23).

PMID: 39683902 PMC: 11643827. DOI: 10.3390/molecules29235745.

Enhancing the antimycobacterial efficacy of pyridine-4-carbohydrazide: linkage to additional antimicrobial agents oxocarboxylic acids.

Pflegr V, Konecna K, Stolarikova J, Osterreicher J, Jandourek O, Kratky M RSC Med Chem. 2024; 16(2):767-778.

PMID: 39568598 PMC: 11575622. DOI: 10.1039/d4md00663a.

β-d-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development.

Hwu J, Panja A, Tsay S, Huang W, Lin S, Yeh C Org Lett. 2024; 26(46):9865-9870.

PMID: 39540692 PMC: 11590094. DOI: 10.1021/acs.orglett.4c03662.

Evaluation of the anticancer effects exerted by 5-fluorouracil and heme oxygenase-1 inhibitor hybrids in HTC116 colorectal cancer cells.

Salerno L, Notaro A, Consoli V, Affranchi F, Pittala V, Sorrenti V J Enzyme Inhib Med Chem. 2024; 39(1):2337191.

PMID: 38634597 PMC: 11028004. DOI: 10.1080/14756366.2024.2337191.

Design, synthesis, and evaluation of the novel ozagrel-paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent.

Zuo C, Yan F, Wang J, Zhu Y, Luo W, Liu Y Front Pharmacol. 2024; 15:1362857.

PMID: 38567356 PMC: 10985144. DOI: 10.3389/fphar.2024.1362857.